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Abstract
The motivation for the work in this article is the setting in which a number of treat-
ments are available for evaluation in phase II clinical trials and where it may be infea-
sible to try them concurrently because the intended population is small. This paper
introduces an extension of previous work on decision-theoretic designs for a series of
phase II trials. The program encompasses a series of sequential phase II trials with
interim decision making and a single two-arm phase III trial. The design is based
on a hybrid approach where the ﬁnal analysis of the phase III data is based on a
classical frequentist hypothesis test, whereas the trials are designed using a Bayesian
decision-theoretic approach in which the unknown treatment eﬀect is assumed to fol-
low a known prior distribution. In addition, as treatments are intended for the same
population it is not unrealistic to consider treatment eﬀects to be correlated. Thus,
the prior distribution will reﬂect this. Data from a randomized trial of severe arthritis
of the hip are used to test the application of the design. We show that the design on
average requires fewer patients in phase II than when the correlation is ignored. Cor-
respondingly, the time required to recommend an eﬃcacious treatment for phase III
is quicker.
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1 BACKGROUND
Before it is authorized by regulatory authorities, a new treatment is ﬁrst tested for tolerability in phase I followed by an exploration
of therapeutic eﬀects in phase II and ﬁnally, eﬃcacy and safety are assessed in phase III (ICH, 1997). The objective for each
phase is diﬀerent and traditionally each study is designed separately. For example, a phase I drug trial might be designed to
identify the maximally tolerated dose and use a group of participants (usually healthy volunteers) at each dose level of a new
drug whereas a nondrug trial may focus on safety assessments only. Once tolerability and safety are established, an exploratory
phase II trial is undertaken to test eﬃcacy against a standard treatment. This may be a single-arm study where observed eﬃcacy
for the test treatment is compared to a ﬁxed and known control, usually a standard treatment. After the test treatment has been
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shown to be reasonably eﬃcacious it is compared to a control (standard treatment or placebo) in a phase III trial. The phase III
trial is typically designed as a two-arm parallel group randomized controlled trial where patients are randomized to either the
test treatment or the control arm (Pocock, 1983).
There is often more than one new intervention (e.g., treatment or procedure) available for testing. This is problematic for
the conventional paradigm of ﬁxed and distinct phases composed of simple two-arm comparisons. This diﬃculty is further
compounded where resources such as patients and money are limited. This is especially true in clinical contexts with small
research populations, for example, a rare disease or for a speciﬁcally targeted subpopulation. In such constrained settings, it is
necessary to design trials in the context of other treatments or trials such that the management and allocation of limited resources
may be optimized and research undertaken as eﬃciently as possible (Senn, 1996).
In this paper, we propose a design motivated by the scenario in which two or more treatments are available for clinical testing
with the intended study population suﬃciently small, or resources suﬃciently limited, that it is not feasible to test all treatments
concurrently. The proposed design is for a series of phase II run one after another and a single phase III trial using treatments
that have been previously tested for tolerability and safety. A decision is made at the end of each phase II trial whether to accept
the test treatment for further study (phase III) or to reject it. In making the latter decision, the decision maker may decide to start
a new phase II trial with a diﬀerent treatment or abandon the entire development plan. As it is essentially a decision problem
whether or not to accept the test treatment for further study, statistical decision theory seems an obvious choice to model the
design of the phase II trial (Julious & Swank, 2005). We propose such an approach that allows the quantiﬁcation of the reward
(or gain) from a future successful phase III trial, if the treatment is accepted for further study, and losses incurred in conducting
the trials. Note that the problem we are investigating is an elaboration of the well-known Secretary Problem where one could
only appoint one candidate from the known 𝑛 candidates to the secretarial position, see, Ferguson (1989a) and commentaries
and responses therein (Ferguson, 1989b; Freeman, 1989; Robbins, 1989; Sakaguchi, 1989; Samuels, 1989) for a summary of
the problem, solutions, and extensions.
There is a relatively limited literature on methods for designing a program of phase II and III trials (see, e.g., Chen & Beckman,
2009; Ding, Rosner, & Müller, 2008; Hee & Stallard, 2012; Pallay, 2001; Rossell, Müller, & Rosner, 2007; Stallard, 2003, 2012;
Stallard & Thall, 2001; Wason, Jaki, & Stallard, 2013; Whitehead, 1986). Of these, eight designs are based on a decision-
theoretic approach, (see, Hee et al., 2015 for a summary of their methods) in which by considering the probable success of the
future of a recommended treatment in a phase III setting, the sample size for each phase II trial can be optimized. A working
group from the Drug Information Association (DIA) Adaptive Design Scientiﬁc Working Group has been working on similar
designs for a program of phase II and III trials in speciﬁc disease areas, namely, diabetes, oncology, and neuropathic pain (see,
Antonijevic et al., 2013; Marchenko et al., 2013; Patel et al., 2012).
The method proposed here extends that was proposed by Hee and Stallard (2012). They considered a program consisting of
a series of sequential phase II trials where at each interim stage a decision is made to continue with recruitment to the current
trial, stop and proceed to a phase III trial with the current treatment, stop and initiate a phase II trial with a new treatment or stop
and abandon the entire program. Unknown parameters were assumed to follow a speciﬁed prior distribution and were assumed
by Hee and Stallard to be independent. In reality, however, treatments targeting the same population may be related. In this
case, information from earlier treatments may inform our opinion of subsequent treatments, which in turn aﬀects their optimal
decision schemes. Therefore, in this paper, we propose an extension which allows correlation between the eﬃcacy parameters
for the test treatments.
2 FRAMEWORK
2.1 Setting
Following Hee and Stallard (2012), we assume at the design stage of a clinical research program that the size of the study
population and the number of treatments available for testing are known and ﬁxed. We plan to conduct a series of single-arm
phase II trials followed by a single randomized controlled phase III trial. We assume that the primary endpoints for both phase
II and III trials are the same and that the responses follow a Bernoulli distribution.
The terms program and development plan are used interchangeably to represent this series of trials. The phase II trials are
conducted one after another with interim analyses. We also assume that treatments already tested in the current program will not
be evaluated further and patients previously recruited into the current program will not join future trials of the current program.
Within each phase II trial, a group of patients is treated in each interim stage and a decision is made based on their observed
responses from the following actions:
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Action A: Stop the current phase II trial and abandon the entire program;
Action P: Stop the current phase II trial and proceed to a two-arm phase III trial with this test treatment compared to the
standard treatment using all the remaining patients;
Action T: Stop the current phase II trial and initiate a new single-arm phase II trial for a diﬀerent treatment; or
Action R: Continue the current phase II trial by recruiting additional patients.
Not all four actions are available for consideration at all interim stages; if all available treatments have been tried then action
T is not available at any interim stage of the trial of the ﬁnal treatment. We also restrict the phase III trial to a minimum sample
size. Thus when only this minimum number of patients remain from the original research population, actions R and T are not
available.
It is assumed that at the end of the phase III trial, the observed data from the trial are analyzed based on a frequentist hypothesis
test. However, in the design stage of the whole development plan we will adopt a Bayesian approach in which the unknown
treatment eﬃcacy parameters are assumed to be random and follow a known prior distribution. That is, the design is based on
a hybrid approach, a combination of classical and Bayesian frameworks.
2.2 Model
Let 𝑁 denote the total size of the population eligible for both phase II and III trials and 𝐾 denote the number of test treat-
ments with 𝑁 and 𝐾 assumed ﬁxed and known. Let 𝑛III,min be the predetermined minimum number of patients required for
the phase III trial and 𝑚𝑘𝑖 be the predetermined ﬁxed number of patients recruited at the 𝑖-th stage of the 𝑘-th phase II trial,
𝑘 = 1,… , 𝐾 . The total number of patients recruited from the ﬁrst stage up to and including the 𝑖-th stage of the 𝑘-th trial is
𝑛𝑘𝑖 =
∑𝑖
𝑗=1 𝑚𝑘𝑗 . Assuming patients’ responses to be independent Bernoulli random variables, let 𝑌𝑘𝑖 be the number of successes
out of the𝑚𝑘𝑖 patients in 𝑖-th stage of trial 𝑘 and 𝑆𝑘𝑖 =
∑𝑖
𝑗=1 𝑌𝑘𝑗 be the accumulated total number of successes out of 𝑛𝑘𝑖 patients
from the ﬁrst 𝑖 stages in trial 𝑘 so that 𝑆𝑘𝑖 ∼ 𝐵𝑖𝑛(𝑛𝑘𝑖, 𝑝𝑘) for 𝑝𝑘, and similarly, 𝑌𝑘𝑖 ∼ 𝐵𝑖𝑛(𝑚𝑘𝑖, 𝑝𝑘). Given 𝑝𝑘, the density function
of 𝑆𝑘𝑖 and 𝑌𝑘𝑖 are 𝑓𝑆|𝑝(𝑠𝑘𝑖|𝑛𝑘𝑖, 𝑝𝑘) = (𝑛𝑘𝑖𝑠𝑘𝑖)𝑝𝑠𝑘𝑖𝑘 (1 − 𝑝𝑘)𝑛𝑘𝑖−𝑠𝑘𝑖 and 𝑓 (𝑦𝑘𝑖|𝑚𝑘𝑖, 𝑝𝑘), respectively.
Suppose 𝑛𝑘+ is the total number of patients in trial 𝑘 and 𝑆𝑘+ is the total number of successes from the 𝑛𝑘+ patients
when action T (stop the current phase II trial and start another with a new test treatment) is taken. During the con-
duct of the current 𝑘-th trial, there is no observation from future trials. Let 𝒏𝒌𝒊 = (𝑛1+,… , 𝑛𝑘−1,+, 𝑛𝑘𝑖, 0,… , 0) be the ran-
dom vector of the number of patients recruited from the preceding trials and from the ﬁrst stage up to and including the
𝑖-th stage of the 𝑘-th trial and 𝑺𝒌𝒊 = (𝑆1+,… , 𝑆𝑘−1,+, 𝑆𝑘𝑖, 0,… , 0) be the corresponding vector of successes observed. Let
𝑺𝒌𝟎 = (𝑆1+,… , 𝑆𝑘−1,+, 0,… , 0) denote the vector of successes out of 𝒏𝒌𝟎 = (𝑛1+,… , 𝑛𝑘−1,+, 0,… , 0) patients observed from
the preceding trials at the start of the 𝑘-th trial; this will be referred to as stage 0. The joint conditional distribution of
𝑺𝒌𝒊 = 𝒔𝒌𝒊 given 𝒏𝒌𝒊 and 𝒑 = (𝑝1,… , 𝑝𝐾 ) at stage 𝑖 in trial 𝑘 is the product of density functions, ℎ𝑺𝒌𝒊|𝒑(𝑺𝒌𝒊 = 𝒔𝒌𝒊|𝒑) =∏𝑘−1
𝑘′=1 𝑓𝑆|𝑝(𝑠𝑘′+|𝑛𝑘′+, 𝑝𝑘′ )𝑓𝑆|𝑝(𝑠𝑘𝑖|𝑛𝑘𝑖, 𝑝𝑘). Note that at stage 𝑖 = 0, 𝑛𝑘𝑖 = 0 and we take 𝑓𝑆|𝑝(0|0, 𝑝𝑘) = 1.
In this proposed design, we assume that the parameters 𝒑 follow some joint prior distribution denoted by the 𝐾-variate
joint density, ℎ𝒑(𝒑). Upon observing the accumulated successes, 𝒔𝒌𝒊, information on 𝒑 is updated and the joint posterior density
obtained using Bayes’ theorem is ℎ𝒑|𝑺𝒌𝒊 (𝒑|𝒔𝒌𝒊) = ℎ𝑺𝒌𝒊|𝒑(𝒔𝒌𝒊|𝒑)ℎ𝒑(𝒑)∕ℎ𝑺𝒌𝒊(𝒔𝒌𝒊)where ℎ𝑺𝒌𝒊 (𝒔𝒌𝒊) = ∫ ⋯∫ ℎ𝑺𝒌𝒊|𝒑(𝒔𝒌𝒊|𝒑)ℎ𝒑(𝒑) d𝒑,
is the marginal joint density of 𝑺𝒌𝒊.
We have noted earlier that patients’ responses are conditionally independent given parameters 𝒑. Therefore, suppose we have
observed 𝑺𝒌𝒊 = 𝒔𝒌𝒊, the posterior marginal density of 𝑌𝑘,𝑖+1 is
𝑔𝑌 |𝑺𝒌𝒊(𝑦𝑘,𝑖+1|𝒔𝒌𝒊,𝒏𝒌𝒊) = ∫ ⋯∫ 𝑓(𝑦𝑘,𝑖+1|𝑚𝑘,𝑖+1, 𝑝𝑘)ℎ𝒑|𝑺𝒌𝒊(𝒑|𝒔𝒌𝒊) d𝒑. (1)
3 UTILITIES AND BACKWARD INDUCTION
3.1 Utilities
At each stage of each trial, the desirability of each action is expressed by some gain or utility function capturing rewards and
costs which will be assumed to depend on the true parameters, 𝒑, the total number of patients, 𝑁 , and the numbers of patients
recruited so far, 𝒏𝒌𝒊. The reward may be the monetary value of taking the action or it could be a value that has no obvious scale
of measurement, such as the value of treatment eﬀectiveness. The cost of conducting a trial is separated into ﬁxed and variable
costs (Patel & Ankolekar, 2007). The costs of phase II and III trials may be diﬀerent due, in part at least, to longer follow-up and
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more comprehensive outcome assessment in studies of the latter type. The ﬁxed costs are costs that are not dependent on the size
of the trial. Let 𝑙II,𝑘 and 𝑙III,𝑘 denote the costs of setting up and conducting phase II and III trials for treatment 𝑘, respectively.
The variable cost, on the other hand, depends on the size of the trial and can be expressed as the cost per patient. Let 𝑐II,𝑘 and
𝑐III,𝑘 denote the cost per patient in a phase II and III trials, respectively, for treatment 𝑘.
Let 𝐺𝑎(𝑘,𝒑,𝒏𝒌𝒊, 𝑁) be the gain function for action 𝑎, 𝑎 ∈ {𝐴, 𝑃 , 𝑇 , 𝑅}, in trial 𝑘 given the sample sizes 𝒏𝒌𝒊 and the true
value of 𝒑. The gain function for each action is described in detail in Sections 4.1 to 4.3. As the true parameters are unknown,
the expected utility function of action 𝑎 can be obtained as the expectation over 𝒑. Having observed responses from the preced-
ing trials and from the ﬁrst stage up to and including the 𝑖-th stage of trial 𝑘, the expected utility of action 𝑎 is the expec-
tation over the joint posterior density of 𝒑 given 𝒔𝒌𝒊. For 𝑎 ∈ {𝐴, 𝑃 }, the expected utility is given by 𝑎(𝑘, 𝒔𝒌𝒊,𝒏𝒌𝒊, 𝑁) =
𝐸(𝐺𝑎(𝑘,𝒑,𝒏𝒌𝒊, 𝑁)|𝒔𝒌𝒊) = ∫ ⋯∫ 𝐺𝑎(𝑘,𝒑,𝒏𝒌𝒊, 𝑁)ℎ𝒑|𝑺𝒌𝒊 (𝒑|𝒔𝒌𝒊) d𝒑. The expected utility function for 𝑎 ∈ {𝑇 ,𝑅} depends on the
expected utility of subsequent actions and we show how they are calculated below (see Sections 4.2 and 4.3). The optimal action
at stage 𝑖 of trial 𝑘 is the one that maximizes the expected gain function, argmax𝑎∈{𝐴,𝑃 ,𝑇 ,𝑅}𝑎(𝑘, 𝒔𝒌𝒊,𝒏𝒌𝒊, 𝑁).
4 EXPECTED UTILITY FUNCTIONS
The utility function is deﬁned relative to an arbitrary reference value (Hilden, 1990). A natural and convenient one is to ﬁx it to
the initial stage of the current trial where no cost is spent. This is because the utility function within each trial does not need to
account for the costs incurred from previous treatments as these costs are common constants during the comparisons of actions
at each stage of the current treatment.
4.1 Expected utility of action A (abandon the program) and action P (proceed to a phase III trial)
Following the design by Hee and Stallard (2012) the utility function we consider in this work is motivated from a commercial
perspective and the expected utility functions of actions A and P have similar forms to those described by them;
𝑎(𝑘, 𝒔𝒌𝒊,𝒏𝒌𝒊, 𝑁) = ⎧⎪⎨⎪⎩
−𝑐II,𝑘𝑛𝑘𝑖, 𝑎 = 𝐴,
∫ ⋯∫ 𝑈 (1 − Φ(𝑧1−𝛼∕2 − 𝜃𝑘√𝑉𝑘))ℎ𝒑|𝑺𝒌𝒊 (𝒑|𝒔𝒌𝒊) d𝒑+
−𝑐II,𝑘𝑛𝑘𝑖 − 𝑐III,𝑘
(
𝑁 −
∑𝑘−1
𝑗=1 𝑛𝑗+ − 𝑛𝑘𝑖
)
− 𝑙III,𝑘, 𝑎 = 𝑃 ,
(2)
where 𝑈 is the gain of identifying the experimental treatment as more eﬀective than the control treatment correctly, 𝜃𝑘 =
log{𝑝𝑘(1 − 𝑝𝐶 )∕(𝑝𝐶 (1 − 𝑝𝑘)) is the log odds ratio, Φ(⋅) is the cumulative standard normal distribution function, 𝑧𝛾 is the upper
100𝛾 percentile of the standard normal density, and 𝑉 is Fisher’s information. The gain 𝑈 can be a ﬁxed constant value or a
function of 𝜃 where the gain depends on the level of eﬃcacy of the experimental treatment (see, e.g., Berry & Ho, 1988). The
notable diﬀerence in our proposed design from Hee and Stallard (2012) is that the expected utility of action P is the expectation
over the joint posterior density.
4.2 Expected utility of action T (start a new phase II trial)
If action T is taken after observation of 𝒏𝒌𝒊 patients, the 𝑘-th trial is abandoned and a new phase II trial is initiated with the
remaining population of size 𝑁 −
∑𝑘−1
𝑗=1 𝑛𝑗+ − 𝑛𝑘𝑖. The expected utility of action T depends on the expected utility of the new
trial and its resulting actions may be found by backward induction (as follows). The expected utility of action T is the expected
utility of the (𝑘 + 1)-th trial less the cost of patients recruited thus far to the 𝑘-th trial, that is
𝑇 (𝑘, 𝒔𝒌𝒊,𝒏𝒌𝒊, 𝑁) = Total(𝑘 + 1, 𝒔𝒌+𝟏,𝟎,𝒏𝒌+𝟏,𝟎, 𝑁) − 𝑐II,𝑘𝑛𝑘𝑖, (3)
where Total(𝑘 + 1, 𝒔𝒌+𝟏,𝟎,𝒏𝒌+𝟏,𝟎, 𝑁) is the expected utility of the (𝑘 + 1)-th trial having observed 𝑺𝒌+𝟏,𝟎 =
(𝑆1+,… , 𝑆𝑘+, 0,… , 0) successes out of 𝒏𝒌+𝟏,𝟎 = (𝑛1+,… , 𝑛𝑘+, 0,… , 0) patients from the ﬁrst 𝑘 trials and is calculated
as shown below (Section 4.4).
We set 𝑇 (𝑘, 𝒔𝒌𝒊,𝒏𝒌𝒊, 𝑁) = −∞ if∑𝑘−1𝑗=1 𝑛𝑗+ + 𝑛𝑘𝑖 ≥ 𝑁 − 𝑛III,min so that action T will not be chosen as the optimum action
at stage 𝑖 of trial 𝑘 since this would leave fewer than the required minimum number of patients for a phase III trial at any point
in the future. Similarly, when 𝑘 = 𝐾 , action T is not available at any interim stage and 𝑇 (𝑘, 𝒔𝑲𝒊,𝒏𝑲𝒊, 𝑁) = −∞ for all 𝑖.
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4.3 Expected utility of action R (continue the current phase II trial)
Action R is to continue the current single-arm phase II trial. The gain from action R after observation of 𝒏𝒌𝒊 patients from
the preceding trials and from the ﬁrst stage up to and including the 𝑖-th stage of trial 𝑘 depends on the action taken based
on the observation from patients recruited in subsequent stages and trials. Consequently, the expected utility of action R is
also obtained by backward induction. Suppose we recruit an additional 𝑚𝑘,𝑖+1 patients to the current trial with 𝑌𝑘,𝑖+1 = 𝑦𝑘,𝑖+1
observed at the (𝑖 + 1)-th stage. The optimal action at this stage is then the action with the highest expected utility function,
max𝑎∈{𝐴,𝑃 ,𝑇 ,𝑅}{𝑎(𝑘, 𝒔𝒌𝒊 + 𝑦𝑘,𝑖+1,𝒏𝒌𝒊 + 𝑚𝑘,𝑖+1, 𝑁)}. The expected utility of action R is the gain from recruiting the additional
𝑚𝑘,𝑖+1 patients averaged over the possible responses given the observed successes from the preceding trials and from the ﬁrst
stage up to and including the 𝑖-th stage of the current trial, that is
𝑅(𝑘, 𝒔𝒌𝒊,𝒏𝒌𝒊, 𝑁) = 𝑚𝑘,𝑖+1∑
𝑦𝑘,𝑖+1=0
max
𝑎∈{𝐴,𝑃 ,𝑇 ,𝑅}
{𝑎(𝑘, 𝒔𝒌𝒊 + 𝑦𝑘,𝑖+1,𝒏𝒌𝒊 + 𝑚𝑘,𝑖+1, 𝑁)} ×
× 𝑔𝑌 |𝑺𝒌𝒊(𝑦𝑘,𝑖+1|𝒔𝒌𝒊,𝒏𝒌𝒊), (4)
where 𝑔𝑌 |𝑺𝒌𝒊 (𝑦𝑘,𝑖+1|𝒔𝒌𝒊,𝒏𝒌𝒊) is the posterior marginal density of 𝑌𝑘,𝑖+1 given 𝑺𝒌𝒊 = 𝒔𝒌𝒊 as given in (1). We set𝑅(𝑘, 𝒔𝒌𝒊,𝒏𝒌𝒊, 𝑁) = −∞ if∑𝑘−1𝑗=1 𝑛𝑗 + 𝑛𝑘𝑖 ≥ 𝑁 − 𝑛III,min, 𝑘 = 1,… , 𝐾 so that action R is not possible.
4.4 Expected utility of the 𝒌-th trial
The 𝑘-th trial starts by recruiting 𝑚𝑘1 patients to the ﬁrst stage. The expected utility of the 𝑘-th trial is obtained by con-
sidering the desirability of sampling 𝑚𝑘1 patients and the possible resulting actions, namely, actions A, P, T and R. The
expected utilities of these actions are given, respectively, by Eqs. (2)–(4) which in turn depend on the expected utilities
of subsequent actions. As there is a ﬁnite sequence of interim stages in the trial the expected utility of the 𝑘-th trial is
solved by computing the expected utilities of all actions at the ultimate stage for all possible responses. At this last stage,
the expected utilities of actions A and P are given by (2), whereas expected utilities of actions T and R are set to −∞ as
discussed in Sections 4.2 and 4.3. The expected utility functions for all actions at the penultimate stage are then solved
based on the values from the ultimate stage and for all possible responses prior to the penultimate stage. Working method-
ically in this iterative manner the expected utility of the 𝑘-th trial is obtained by backward induction. The computation
of the expected utility of the trial and optimum sequential scheme is similar to the one described in Hee and Stallard
(2012).
Suppose at the start of trial 𝑘,𝑺𝒌𝟎 = (𝑆1+,… , 𝑆𝑘−1,+, 0,… , 0) successes out of 𝒏𝒌𝟎 = (𝑛1+,… , 𝑛𝑘−1,+, 0,… , 0) patients were
observed from the preceding trials, the expected utility of the 𝑘-th trial is determined by maximizing the expected utility of each
possible action (i.e., averaging it over all possible values of 𝑌𝑘1) less the cost of conducting the 𝑘-th phase II trial. The expected
utility is written as
Total(𝑘, 𝒔𝒌𝟎,𝒏𝒌𝟎, 𝑁) = 𝑚𝑘1∑
𝑦𝑘1=0
max
𝑎∈{𝐴,𝑃 ,𝑇 ,𝑅}
{𝑎(𝑘, 𝒔𝒌𝟏,𝒏𝒌𝟏, 𝑁)} 𝑔𝑌 |𝑺𝒌𝟎(𝑦𝑘1|𝒔𝒌𝟎,𝒏𝒌𝟎) − 𝑙II,𝑘,
where 𝑔𝑌 |𝑺𝒌𝟎(𝑦𝑘1|𝒔𝒌𝟎,𝒏𝒌𝟎) is the posterior marginal density of 𝑌𝑘1 given 𝒔𝒌𝟎, obtained as shown in (1), that is,
𝑔𝑌 |𝑺𝒌𝟎 (𝑦𝑘1|𝒔𝒌𝟎,𝒏𝒌𝟎) = ∫ ⋯∫ 𝑓 (𝑦𝑘1|𝑚𝑘1, 𝑝𝑘)ℎ𝒑|𝑺𝒌𝒊 (𝒑|𝒔𝒌𝟎) d𝒑 and the individual expected utilities, 𝑎(𝑘, 𝒔𝒌𝟏,𝒏𝒌𝟏, 𝑁), are given
above (Sections 4.1–4.3). At the ﬁrst stage of trial 𝑘, 𝑆𝑘1 = 𝑌𝑘1 and 𝑛𝑘1 = 𝑚𝑘1, therefore, 𝑺𝒌𝟏 = (𝑆1+,… , 𝑆𝑘−1,+, 𝑌𝑘1, 0,… , 0)
and 𝒏𝒌𝟏 = (𝑛1+,… , 𝑛𝑘−1,+, 𝑚𝑘1, 0,… , 0).
The expected utility of the whole program Total(𝒔𝟏𝟎,𝒏𝟏𝟎, 𝑁), is then obtained. If this is greater than 0 then it is worthwhile
to start the trial by recruiting the ﬁrst 𝑚11 patients to the ﬁrst trial. Otherwise, the optimal decision is not to start the program at
all.
6 HEE ET AL.
5 PRIOR DISTRIBUTION
One possible form of the 𝐾-variate beta distribution is one that follows the multivariate distribution family introduced by Sar-
manov, described by Lee (1996). The joint density function is
ℎ𝒑(𝑝1,… , 𝑝𝐾 ) =
(
𝐾∏
𝑘=1
𝑓𝑝(𝑝𝑘)
)(
1 +𝑅Ω𝐾 (𝑝1,… , 𝑝𝐾 )
)
, (5)
with
𝑅Ω𝐾 (𝑝1,… , 𝑝𝐾 ) =
𝐾−1∑
𝑗1=1
𝐾∑
𝑗2=𝑗1+1
𝜔𝑗1,𝑗2
𝜙
(
𝑝𝑗1
)
𝜙
(
𝑝𝑗2
)
+
+
𝐾−2∑
𝑗1=1
𝐾−1∑
𝑗2=𝑗1+1
𝐾∑
𝑗3=𝑗2+1
𝜔𝑗1,𝑗2,𝑗3
𝜙
(
𝑝𝑗1
)
𝜙
(
𝑝𝑗2
)
𝜙
(
𝑝𝑗3
)
+⋯ + 𝜔1,2,…,𝐾
𝐾∏
𝑗=1
𝜙
(
𝑝𝑗
)
,
where 𝜙(𝑝𝑘) is a nonconstant mixing function bounded by ∫ ∞−∞ 𝜙(𝑝𝑘)𝑓𝑝(𝑝𝑘) d𝑝𝑘 = 0 and the mixing parameter Ω𝐾 ={
𝜔𝑗1,𝑗2
, 𝜔𝑗1,𝑗2,𝑗3
,… , 𝜔1,2,…,𝐾
}
. Lee proposed 𝜙(𝑝𝑘) = 𝑝𝑘 − 𝜇𝑘 where 𝜇𝑘 is the expected value of 𝑝𝑘. The elements of Ω𝐾 are
chosen such that they satisfy the condition 1 + 𝑅Ω𝐾
(
𝑝1,… , 𝑝𝐾
) ≥ 0 for all 𝒑 and when each element equals zero, then all 𝐾
treatments are independent.
The joint posterior density is
ℎ𝒑|𝑺
(
𝑝1,… , 𝑝𝐾 |𝑠1,… , 𝑠𝐾) ={ 𝐾∏
𝑘=1
𝑓𝑝|𝑆(𝑝𝑘|𝑠𝑘)}{1 +𝑅Ω𝐾 (𝑝1,… , 𝑝𝐾)1 +𝐷Ω𝐾 (𝑠1,… , 𝑠𝐾)
}
(6)
where 𝑓𝑝|𝑆(𝑝𝑘|𝑠𝑘) = 𝑝𝑎𝑘+𝑠𝑘−1𝑘 (1 − 𝑝𝑘)𝑏𝑘+𝑛𝑘−𝑠𝑘−1∕𝐵(𝑎𝑘 + 𝑠𝑘, 𝑏𝑘 + 𝑛𝑘 − 𝑠𝑘) is the marginal posterior density and
𝐷Ω𝐾
(
𝑠1,… , 𝑠𝐾
)
=
𝐾−1∑
𝑗1=1
𝐾∑
𝑗2=𝑗1+1
𝜔𝑗1,𝑗2
𝜓
(
𝑠𝑗1
)
𝜓
(
𝑠𝑗2
)
+
+
𝐾−2∑
𝑗1=1
𝐾−1∑
𝑗2=𝑗1+1
𝐾∑
𝑗3=𝑗2+1
𝜔𝑗1,𝑗2,𝑗3
𝜓
(
𝑠𝑗1
)
𝜓
(
𝑠𝑗2
)
𝜓
(
𝑠𝑗3
)
+⋯ + 𝜔1,2,…,𝐾
𝐾∏
𝑗=1
𝜓
(
𝑠𝑗
)
,
where 𝜓
(
𝑠𝑘
)
=
(
𝑠𝑘 − 𝜇𝑘𝑛𝑘
)
∕
(
𝑎𝑘 + 𝑏𝑘 + 𝑛𝑘
)
.
6 APPLICATION
6.1 The Warwick arthroplasty trial (WAT)
In order to illustrate the characteristics of the development plan of a series of trials with correlated treatment eﬃcacy we use data
from the Warwick arthroplasty trial (WAT) (Costa et al., 2012). This was a two-arm parallel group randomized controlled trial
that assessed function after either total hip arthroplasty or resurfacing arthroplasty in patients with severe arthritis of the hip. The
latter treatment group was the newer implant procedure (experimental) and the former the standard procedure (control). Patients
were recruited between May 2007 and February 2010 and 60 of the total 126 patients were randomized to the experimental
arm. One of the study endpoints was hip function at three months postsurgery assessed using the Oxford hip score (Dawson,
Fitzpatrick, Carr, & Murray, 1996); this is often categorized into either poor (score, 0–26), fair (score, 27–33), good (score,
34–41), or excellent (score, 42–48) function (Costa et al., 2012).
Although there was only one experimental treatment in WAT, it is not uncommon in surgical trials to have more than one
procedure that diﬀer in the types of material and/or technical aspects of the operation. This design of a series of treatment where
their eﬀects are correlated is ideal for such surgical trials where the intended research population is small and there are more
than one procedure available such that it is infeasible to try them concurrently.
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6.2 Bivariate case
In our illustration, we assume that there are two (𝐾 = 2) newer resurfacing arthroplasty procedures that diﬀer in the technical
aspects of the operation available for single-arm phase II clinical trial and only one can proceed to a phase III trial where the
control treatment would be total hip arthroplasty. We also assume that the primary endpoint is a binary outcome where a good
or excellent function of the Oxford hip score at three months postsurgery is considered as a success (represented numerically
as 1) whereas a poor or fair function is considered as a failure (0). The three-month hip function score provides a convenient
measure of the success or failure of the procedure in our hypothetical phase II trial.
For 𝐾 = 2, the bivariate density function in Eq. (5) is ℎ𝒑(𝑝1, 𝑝2) = 𝑓𝑝(𝑝1)𝑓𝑝(𝑝2)(1 + 𝜔𝜙(𝑝1)𝜙(𝑝2)) where 𝜙(𝑝𝑘) is taken to
be 𝑝𝑘 − 𝜇𝑘, 𝑘 = 1, 2, and 𝜇𝑘 is the expected value of 𝑝𝑘. The correlation coeﬃcient of 𝑝1 and 𝑝2 is given by 𝜌 = 𝜔𝜎1𝜎2 where
𝜎2
𝑘
is the variance of 𝑝𝑘 and the mixing parameter, 𝜔, satisﬁes the condition
max
{
−1
𝜇1𝜇2
,
−1
(1 − 𝜇1)(1 − 𝜇2)
}
≤ 𝜔 ≤ min
{
1
𝜇1(1 − 𝜇2)
,
1
𝜇2(1 − 𝜇1)
}
, (7)
so that 𝜌 ∈ [−1, 1] (Lee, 1996). A range of prior distributions of this form are considered below.
6.3 Illustration of the bivariate case
From the published results (Costa et al., 2012), we assume for designing the series of trials that the probability of success
of the control treatment is 𝑝𝐶 = 0.5. We also assume that the probability of each treatment follows the same marginal prior
distribution, as we believe a priori that both treatments are equally eﬀective. In order to understand the operating characteristics
of the design we consider the following prior density functions; 𝐵𝑒𝑡𝑎(1, 1) which is equivalent to obtaining information from a
uniform distribution, 𝐵𝑒𝑡𝑎(0.12, 0.08), 𝐵𝑒𝑡𝑎(3, 2), 𝐵𝑒𝑡𝑎(12, 8), and 𝐵𝑒𝑡𝑎(143.4, 95.6) which have expected value 0.6, indicating
a prior belief that the experimental treatment eﬃcacy is greater than 𝑝𝐶 , but variances ranging from 0.20 to 0.001. We also
consider prior distributions with expected value less than 𝑝𝐶 , namely, 𝐵𝑒𝑡𝑎(8, 12) and 𝐵𝑒𝑡𝑎(8.792, 11.65) which have the same
variance of 0.0114 but diﬀerent expected values, 0.40 and 0.43, respectively, and 𝐵𝑒𝑡𝑎(2, 3) and 𝐵𝑒𝑡𝑎(7, 10.5) which have the
same expected value, 0.40, but diﬀerent variances, 0.04 and 0.0130, respectively. Note that it is unlikely in practice to select
a highly informative prior such as 𝐵𝑒𝑡𝑎(12, 8) and 𝐵𝑒𝑡𝑎(143.4, 95.6) or a U-shaped distribution such as 𝐵𝑒𝑡𝑎(0.12, 0.08) and
𝐵𝑒𝑡𝑎(0.84, 0.56) but they are included here for illustration.
We also need to make some (albeit fairly crude) assumptions about the costs of diﬀerent aspects of the design. For simplicity,
the ﬁxed and variable costs for both treatments are assumed to be equal for the two experimental treatments. Assume that a
reward when the phase III trial is successful (new treatment is statistically signiﬁcant better than the control treatment at two
sided 𝛼 = 0.05 level) is a gain of 𝑈 = £3 million, and costs of setting up and the personnel needed for a phase II and III trials
are 𝑙II,𝑘 = £30 000 and 𝑙III,𝑘 = £300 000, respectively. The cost per patient in both phase II and III setting is set to be equal, that
is, 𝑐II,𝑘 = 𝑐III,𝑘 = £750.
We computed the optimal designs and strategies with the following values: a projected total size of the population, 𝑁 =
350, 𝑚𝑘𝑖 = 5, for all 𝑘 and 𝑖 (the subscripts are suppressed from henceforth), and the minimum size of phase III, 𝑛III,min = 300
for prior distributions stated above and diﬀerent values of𝜔 = 0 and 4where the latter value is the maximum integer that satisﬁes
the condition shown in (7) and the former is when the treatment eﬃcacy is independent.
Figure 1 shows the decision scheme for optimal actions for the ﬁrst phase II trial for 𝐵𝑒𝑡𝑎(1, 1) and 𝐵𝑒𝑡𝑎(8.792, 11.65). As an
illustration, Fig. 1(b) shows that if there were at least one success out of the ﬁrst ﬁve patients then the optimal action is action
R (continue recruitment to the current trial). If no success is observed then the optimal action is action T (to stop the current
trial and start a new phase II trial with the second treatment). The minimum number of patients needed to proceed to the phase
III trial (action P) is 10 (of which all must be successes) and the maximum number needed is 45 (of which at least 28 must be
successes).
Table 1 shows the operating characteristics of the development plan for various prior densities. We sampled data from a
Bernoulli distribution with 𝑝 = 0.52, the proportion of patients from WAT resurfacing arthroplasty (experimental arm) with
good/excellent function at three months postsurgery, 1000 times for each scenario. For each simulation, batches (size 𝑚 = 5)
were generated in turn and the optimum action, determined from the decision scheme, taken, for each of the 10 scenarios
(R code available as a web supplement). During the ﬁrst trial, after accumulating data from each batch, the available actions
were to continue to accumulate data for treatment 1, to take action T, to take action P, or to stop the development program (action
A). During the trial for treatment 2, action T was not available. The number of occasions that various terminal actions were taken
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F IGURE 1 Decision rules for optimal actions for the ﬁrst phase II trial based on (a) 𝐵𝑒𝑡𝑎(1, 1) and 𝜌 = 0 (equivalently, 𝜔 = 0), (b) 𝐵𝑒𝑡𝑎(1, 1)
and 𝜌 = 0.33 (equivalently, 𝜔 = 4), (c) 𝐵𝑒𝑡𝑎(8.792, 11.65) and 𝜌 = 0 (equivalently, 𝜔 = 0), and (d) 𝐵𝑒𝑡𝑎(8.792, 11.65) and 𝜌 = 0.046 (equivalently,
𝜔 = 4)
for the ﬁrst and second treatments, the median and range of the number of participants needed are also summarized. The same
simulated data were used for each scenario, allowing us to make direct comparison between scenarios.
The estimated proportion of success from the WAT resurfacing arthroplasty arm was 0.52; slightly higher than the historical
control 𝑝𝐶 = 0.50 we assumed for the trial design but lower than 0.60, the expected value of some of the informative prior
densities shown in Table 1. The proportion of times action P was taken increased as the variance of the prior density decreases
(from 0.20 to 0.001) because the minimum threshold to take action P lowers accordingly. In the case of prior 𝐵𝑒𝑡𝑎(8, 12) whose
expected value (0.40) was less than 𝑝𝐶 the expected gain was −0.0022, that is, it was not worthwhile starting the program at all.
As we see from Fig. 1, the optimal decision schemes for treatment 1 do not diﬀer much when both treatments have the same
positive prior and the correlation changes from zero to nonzero, and we observed similar operating characteristics in Table 1
where the proportions of actions T and P taken at treatment 1 were identical or very similar regardless of the correlation. The
correlation aﬀects the expected utility of the second treatment because responses from treatment 1 inform the prior of treatment
2. In Fig. 1(c), the treatment eﬀects are independent and so the expected utility of action T which depends on the number of
patients recruited to the ﬁrst treatment is constant because it does not depend on the responses from treatment 1. Thus, there
is a straight cut-oﬀ between taking actions T and A. However, when there is some correlation between the treatment eﬀects
(see, Fig. 1(d)), the expected utility of action T depends on the responses from the ﬁrst treatment and so we observe a more
gradual shift in its value as the number of successes changes. Supporting Information Figs. S1–S3 show the decision schemes
for treatment 2 after observing responses from 𝑛1+ = 10 patients from treatment 1 for marginal priors𝐵𝑒𝑡𝑎(3, 2), 𝐵𝑒𝑡𝑎(1, 1), and
𝐵𝑒𝑡𝑎(2, 3) when the treatment eﬀects are independent and correlated. The continuation region for treatment 2 changes subtly
depending on the number of successes, 𝑠1+, when the treatment eﬀects are correlated.
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F IGURE 2 Decision rules for optimal actions for the ﬁrst phase II trial based on (a) 𝐵𝑒𝑡𝑎(3, 2), 𝜔12 = 𝜔13 = 𝜔23 = 4 and 𝜔123 = −3, (b)
𝐵𝑒𝑡𝑎(1, 1), 𝜔12 = 𝜔13 = 𝜔23 = 4 and 𝜔123 = 0, and (c) 𝐵𝑒𝑡𝑎(2, 3), 𝜔12 = 𝜔13 = 𝜔23 = 4 and 𝜔123 = 3 when there are 𝐾 = 3 treatments available
6.4 Trivariate case
We also explore the feasibility and characteristics of the design when 𝐾 = 3. Lee (1996) showed that any subvector
(𝑝
𝑘
′
1
,… , 𝑝
𝑘
′
𝑚
), 1 ≤ 𝑘′1 < 𝑘′2 < … < 𝑘′𝑚 ≤ 𝐾 has a joint density of the form (5). This implies that 1 +𝑅Ω
𝑘
′
𝑚
(𝑝
𝑘
′
1
,… , 𝑝
𝑘
′
𝑚
) ≥ 0.
Therefore, we assume the pairwise mixing parameters, 𝜔12, 𝜔13, and 𝜔23 are bounded as in (7) and the lower and upper bounds
of 𝜔123 are given in Supporting Information Appendix A.
Following earlier illustrations, we consider all treatments’ eﬃcacies to have the same marginal beta prior density,
𝑝𝑘 ∼ 𝐵𝑒𝑡𝑎(𝑎𝑘, 𝑏𝑘), 𝑘 = 1, 2, 3, with 𝑎𝑘 = 𝑎 and 𝑏𝑘 = 𝑏 and 𝜔12 = 𝜔13 = 𝜔23 = 𝜔. As shown in the Supporting Information
Appendix A, the lower and upper bounds for 𝜔123 are
max
{
−[1 + 3𝜔(1 − 𝜇)2]
(1 − 𝜇)3
,
−[1 + 𝜔𝜇2 − 2𝜔𝜇(1 − 𝜇)]
𝜇2(1 − 𝜇)
}
≤ 𝜔123 ≤ min
{
1 + 3𝜔𝜇2
𝜇3
,
1 − 2𝜔𝜇(1 − 𝜇) + 𝜔(1 − 𝜇)2
𝜇(1 − 𝜇)2
}
. (8)
Figure 2 shows the decision scheme for the ﬁrst treatment for 𝑎 = 3, 𝑏 = 2 with 𝜔 = 4 and 𝜔123 = −3 (Fig. 2a), 𝑎 = 1, 𝑏 = 1
with 𝜔 = 4 and 𝜔123 = 0 (Fig. 2b), and 𝑎 = 2, 𝑏 = 3 with 𝜔 = 4 and 𝜔123 = 3 (Fig. 2c). Analogous to the bivariate case, the
pairwise mixing parameter, 𝜔, takes the maximum integer that satisﬁes condition (7) and the trivariate mixing parameter, 𝜔123
takes the maximum integer that satisﬁes condition (8).
In the trivariate case, the continuation region (action C) shifts up suggesting that more successes are needed before stopping the
trial and proceeding to a phase III trial with the ﬁrst treatment. Otherwise, the optimal action is to try subsequent treatments. The
expected utilities of the whole program, Total(𝒔𝟏𝟎,𝒏𝟏𝟎, 𝑁) are 0.555, 0.454, and 0.203 for 𝐵𝑒𝑡𝑎(3, 2), 𝐵𝑒𝑡𝑎(1, 1), and 𝐵𝑒𝑡𝑎(2, 3)
prior distributions, respectively. They are higher than the bivariate case which is expected as in this setting we have more
treatments to learn from.
7 DISCUSSION
7.1 Correlation and prior distributions
The predecessor of this design, proposed by Hee and Stallard (2012), does not consider the correlation between the eﬃcacy of
the treatments. We showed here that because of the correlation, responses from the ﬁrst treatment update the prior density of
the second treatment and consequently, the optimal decision scheme for the second treatment is more sensitive to an ineﬀective
treatment, that is, the action C region shifts higher when there is correlation, making it more diﬃcult to proceed to a phase III
trial with the second treatment but easier to stop the second trial and abandon the whole program than when it is independent
(see, Supporting Information Figs. S1–S3).
The Sarmanov family of distributions is slightly more ﬂexible than those of the Farlie–Gumbel–Morgenstern (FGM) distri-
butions; Lee (1996) showed that the correlation coeﬃcients of the bivariate Sarmanov have wider ranges. However, when both
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marginal prior distributions are identical beta distributions with parameters 𝑎, 𝑏 ≥ 1, the correlation is limited to the interval
[−1∕3, 1∕3], the same limitation as the FGM distributions. As the limit of the level of correlation is low there is little diﬀerence
in the operating characteristics between correlated and independent cases as seen in the expected gain of the whole development
program (Table 1). The bivariate beta distribution proposed by Olkin and Trikalinos (2015) is more ﬂexible than the Sarmanov
form as it allows correlations over the full range [-1,1] has no closed form expression. Therefore, the posterior distribution
could only be calculated numerically. The number of terms in its joint density increases by order of 2𝑘 − 1 which may be more
computationally inconvenient than Sarmanov when 𝐾 > 3.
In our illustrations the prior densities for both treatments are assumed to be the same. Nevertheless, the order in which the
treatments are entered into the study is important. For instance, the results from three prior densities that are more reasonable in
practice, that is, 𝐵𝑒𝑡𝑎(3, 2), 𝐵𝑒𝑡𝑎(1, 1), and 𝐵𝑒𝑡𝑎(2, 3) indicate that the second treatment is more likely than the ﬁrst treatment
to proceed to a phase III setting. This suggests that as the number of patients available for phase II becomes smaller there is a
higher probability of proceeding to a phase III trial than would have been the case, all other things being equal, earlier in the
program.
In some settings, such as a scenario where a large funding body is funding a series of clinical trials with treatments from
diﬀerent drug classes for the same population, the prior densities may be diﬀerent. It can be seen that again the ordering
of treatments to be tested in the program is important with similar characteristics as when both treatments have the same
marginal prior density, that is, the second treatment has a higher chance to proceed to a phase III setting (see Supporting
Information Table S1). Supporting Information Table S1 presents results from simulations under four scenarios; two of which
started with a treatment with a more informative prior followed by one with a less informative prior and the other two sce-
narios vice versa. Based on the expected utility of the whole program, treatments with less informative prior densities should
be selected as the ﬁrst treatments for the program. We achieve higher expected utility because we learn more about treatment
eﬃcacy.
The challenge in a Bayesian methodology is the speciﬁcation of the prior distribution which should reﬂect one’s belief in the
values of parameters of the prior distribution of the treatment eﬀect. In the speciﬁcation of the prior distribution one may estimate
the mean of the treatment eﬃcacy and its variance from previously conducted studies as suggested above. In the absence of data,
one may elicit the prior distributions and there is a considerable literature on this area (see, e.g., Chaloner, Church, Louis, &
Matts, 1993; O’Hagan, 1998) and case studies by Hampson, Whitehead, Eleftheriou, and Brogan (2014); Kinnersley and Day
(2013). In our illustration, the mixing parameters, 𝜔𝑖𝑗 , and equivalently, the correlation coeﬃcients, 𝜌, were chosen in order to
compare highly correlated treatment eﬀects with independent cases. We envisage that the elicitation of the correlation coeﬃcient
to be conducted at the same time as the prior distributions. A possibility is to elicit from experts whether or not their beliefs of
the density of 𝑝2 would change given the marginal of 𝑝1 and responses from 𝑛1+ patients and the magnitude and direction of any
change.
7.2 Expected utility
The utility functions we proposed here may be modiﬁed to represent similarly realistic alternatives in other settings. For example,
when action A taken the program is abandoned and patients yet to be recruited to the trial would continue with their standard
treatment. The utility of action A could include the gain that the remaining 𝑁 −
∑𝑘−1
𝑗=1 𝑛𝑗+ − 𝑛𝑘𝑖 patients could get from the
standard treatment less the cost of patients recruited to the 𝑘-th trial so far, that is, 𝐺𝐴(𝑘,𝒑,𝒏𝒌𝒊, 𝑁) = 𝑈𝑠(𝑁 −
∑𝑘−1
𝑗=1 𝑛𝑗+ −
𝑛𝑘𝑖) − 𝑐II,𝑘𝑛𝑘𝑖, where 𝑈𝑠 is the gain achieved from the standard treatment and may be set to a ﬁxed value that is relative to 𝑈
or a function of the eﬃcacy of the standard treatment. In principle, 𝑈𝑠 could be a function of the treatment eﬃcacy and then
the expected gain of action A is obtained by taking expectation over all possible values of the true eﬃcacy of the standard
treatment. We could also consider the loss incurred from taking a wrong decision, for example, abandoning the whole program
(action A) when one of the experimental treatments is actually better than the standard treatment by making 𝑈𝑠 a function of
all parameters. The utility function can also be deﬁned as the beneﬁt of health outcome such as quality of life, for example,
expressed in quality-adjusted life years (QALY).
7.3 Computational time
It is undoubtedly more challenging to run a series of decision-theoretic trials such as we proposed than a ﬁxed design as recruit-
ment may need to be suspended while patients’ responses are collected before a decision is made. However, the time taken to
stop the current treatment and try a new one is reduced if the decision-theoretic trial stops early. An additional challenge is
that the computation is complex and time consuming with dynamic programming. This complexity is compounded further by
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the correlation between the unknown parameters, 𝒑. The calculation of expected utilities of each action at each stage depends
on the posterior density of 𝒑 which depends on responses from all preceding trials and stages within them. The computation
time increases rapidly with increasing number of trials and number of interim stages; the computation time is ﬁve times longer
when the number of stages increases from 10 to 20, and 42 times longer from 10 to 30. The expected utility of the program, as
expected, increases as 𝑚 decreases. In a bivariate example with prior 𝐵𝑒𝑡𝑎(3, 2) keeping all values to be same as above except
𝑁 = 360 and for diﬀerent values of 𝑚 = 5, 10, 15, 20, that is, 12 to 3 interim stages, the expected utilities are 0.4963, 0.4950,
0.4932, and 0.4913 (results not shown). In our trivariate illustration, the computational time increases from a few minutes to a
few hours.
7.4 Limitation
A limitation of our proposed design is that the primary endpoints for phase II and III trials are binary. This may not be true for
trials in other disease areas such as oncology where it is more common to have binary response in phase II but time-to-event
outcome in phase III. Similarly, other rare diseases may have continuous or time-to-event outcome as the primary endpoint in
the phase III trial. In these cases, the Sarmanov beta-binomial distribution is still applicable in modeling the correlation between
treatments but an additional joint model is necessary to indicate the association between the phase II endpoint and the phase III
endpoint. This is the topic of ongoing work. Another scenario is when the endpoints in phases II and III are the same but are not
binary. In such case, an alternative to the Sarmanov distribution would be necessary to model the correlation between endpoints
for diﬀerent treatments.
7.5 Further work
Although not limited to this case, as shown by the illustration of a surgical trial, the sequential design proposed in this paper is
motivated by the scenario of a small population such as a rare disease where although there is more than one treatment available
for a clinical trial only one can be evaluated at a time because of the limited resources. In a larger population, there is an option
to run experimental treatments concurrently. Designs proposed by, for example, Bretz, Schmidli, König, Racine, and Maurer
(2006); Hobbs, Chen, and Lee (2016); Rossell et al. (2007); Stallard and Thall (2001); and Stallard and Todd (2003), allow a
few treatments to be tested concurrently with treatment dropped at interim stages for futility. In particular, designs by Rossell
et al. (2007), and Stallard and Thall (2001) are based on optimal decision-theoretic framework. The Sarmanov multivariate
distribution is capable in accommodating concurrently run trials as the posterior joint distribution is obtained as shown in (6)
but the backward induction will be computationally complex.
An alternative to the proposed design is to assume that 𝑝1,… , 𝑝𝐾 are conditionally independently and identically distributed
with 𝐵𝑒𝑡𝑎(𝑎, 𝑏) and we assume an appropriate hyperprior distribution for the parameters (𝑎, 𝑏). The interest is then to ﬁnd the
joint posterior density of the hyperparameters (𝑎, 𝑏) which then estimates the density function of 𝑝𝑘. Designs proposed by Ding
et al. (2008) and Rossell et al. (2007) make use of this hierarchical model where one does not need to explicitly deﬁne the
correlation between probability of success to update the density function of another parameter.
One of the assumptions underlying this development plan is that treatments that have been tested and subsequently abandoned
cannot be evaluated further in the same program. A possible extension to this program is to allow the old treatments to rejoin
the program in the phase III evaluation. In this setting, one may have additional actions to choose in each interim stage, that is,
an action where the current phase II trial is stopped and a phase III trial is initiated with the rejoined treatment.
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